**Health**
## Oral Breakthrough: Wegovy Tablet Now Available Privately in UK for Weight Management
**London, UK** – The landscape of weight management in the UK is evolving with the introduction of an oral formulation of semaglutide, known as Wegovy, now privately available in pharmacies across the country. This once-daily tablet offers a new option for individuals grappling with obesity or overweight conditions complicated by co-morbidities.
The oral medication, developed by the same manufacturers as the popular injectable Wegovy (semaglutide jab), marks a significant step forward by providing a non-injectable alternative for those seeking pharmaceutical support for weight loss.
**Understanding the Treatment:**
Wegovy’s active ingredient, semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking a natural hormone that regulates appetite and food intake, leading to reduced hunger, increased feelings of fullness, and slower gastric emptying. These mechanisms collectively contribute to a significant reduction in calorie intake and subsequent weight loss when combined with a reduced-calorie diet and increased physical activity.
**Access and Eligibility:**
Crucially, access to the Wegovy tablet is currently **private**, meaning it is not yet available via the National Health Service (NHS). Patients interested in this treatment must obtain a prescription from a qualified healthcare professional, following a thorough medical assessment.
Eligibility criteria typically align with those for the injectable form:
* Adults with a Body Mass Index (BMI) of 30 kg/m² or higher (classified as obese).
* Adults with a BMI of 27 kg/m² or higher (classified as overweight) who also have at least one weight-related comorbidity, such as type 2 diabetes, high blood pressure, or dyslipidaemia.
**Important Considerations:**
While the introduction of an oral GLP-1 agonist is a significant advancement, healthcare professionals underscore that medication is just one component of a comprehensive weight management strategy. Successful outcomes are invariably linked to concurrent adoption of a healthy diet and regular physical activity.
Patients considering the Wegovy tablet should be aware of potential side effects, which commonly include gastrointestinal issues such as nausea, diarrhoea, constipation, and vomiting. These should be discussed thoroughly with a prescribing clinician, who will also assess the overall suitability of the treatment based on an individual’s medical history and current health status.
The availability of the Wegovy tablet adds another vital tool to the arsenal against the growing obesity epidemic in the UK, offering a less invasive option for those who may prefer an oral treatment over injections. Further discussions around potential NHS commissioning for the oral form are anticipated as real-world data accrues and its impact on public health becomes clearer.
Individuals considering weight loss medication are urged to consult their doctor or a specialist weight management clinic to determine if Wegovy, or any other treatment, is appropriate for their specific health profile and needs.
